en
More than 70% of drug candidates worldwide are chiral. Typically, only one enantiomer or diastereomer is biologically active or desirable — making the production of enantiopure compounds imperative. For small molecule drugs, separation via crystallization is often vastly more economical and environmentally favorable than traditional chromatography, particularly at early and commercial manufacturing scales.
A highly effective and widely used approach to separating a desired enantiomer from a racemic mixture via diastereomeric salt formation and selective crystallization. We provide comprehensive, tailored resolution programs including:
Conventional chiral resolution methods are theoretically limited to a 50% maximum yield per cycle. Crystal Pharmatech surpasses this limitation by combining active racemization with the targeted, continuous crystallization of a single enantiomer directly from its racemic mixture — a strategy known as deracemization or dynamic resolution.
Crystal Pharmatech does not rely on trial and error. We have established a highly systematic method for chiral purification based on Ternary Phase Diagrams — a powerful predictive tool that provides a fundamental understanding of the thermodynamics governing your chiral system.
Based on these diagrams, the exact feasibility of purifying a chiral drug molecule by crystallization can be immediately determined — guiding us directly to optimal process conditions and eliminating guesswork from your development program.
| Crystallization-Based Separation | Chromatographic Separation |
|---|---|
| Lower cost per kilogram at scale | High solvent and resin costs at scale |
| Readily scalable to commercial volumes | Scale-up complexity and equipment constraints |
| Minimal solvent waste; more sustainable | High solvent consumption and waste generation |
| Integrates naturally with API crystallization workflow | Requires separate downstream processing step |
| No chiral stationary phase — no IP/supply constraints | Dependence on specialized chiral stationary phases |
Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.
Our capabilities span three specialized platforms:
Small Molecule
Crystal Bio Solutions
Crystal NAX
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.
Subscribe to be the first to get the updates!
